|
US6248363B1
(en)
*
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
US20030236236A1
(en)
*
|
1999-06-30 |
2003-12-25 |
Feng-Jing Chen |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
|
EP2415462A1
(en)
*
|
1999-12-23 |
2012-02-08 |
Mayne Pharma International Pty Ltd. |
Improved pharmaceutical compositions for poorly soluble drugs
|
|
GB0012448D0
(en)
|
2000-05-24 |
2000-07-12 |
Astrazeneca Ab |
New process
|
|
DE10026698A1
(de)
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
|
GB0015239D0
(en)
*
|
2000-06-21 |
2000-08-16 |
Biochemie Gmbh |
Organic compounds
|
|
GB0104752D0
(en)
*
|
2001-02-27 |
2001-04-18 |
Astrazeneca Ab |
Pharmaceutical compositions
|
|
JP2004534811A
(ja)
*
|
2001-06-22 |
2004-11-18 |
ファイザー・プロダクツ・インク |
ポリマーと薬剤の集合体を含む医薬組成物
|
|
MXPA04007433A
(es)
|
2002-02-01 |
2004-10-11 |
Pfizer Prod Inc |
Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
|
|
US7259186B2
(en)
*
|
2002-12-17 |
2007-08-21 |
Abbott Laboratories |
Salts of fenofibric acid and pharmaceutical formulations thereof
|
|
US20080051411A1
(en)
*
|
2002-12-17 |
2008-02-28 |
Cink Russell D |
Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
|
|
US20040115287A1
(en)
*
|
2002-12-17 |
2004-06-17 |
Lipocine, Inc. |
Hydrophobic active agent compositions and methods
|
|
EP1572190B1
(en)
*
|
2002-12-17 |
2007-04-18 |
Abbott GmbH & Co. KG |
Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
|
|
CL2004001884A1
(es)
*
|
2003-08-04 |
2005-06-03 |
Pfizer Prod Inc |
Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
|
|
US8377952B2
(en)
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
|
US8025899B2
(en)
*
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
|
US20060003002A1
(en)
*
|
2003-11-03 |
2006-01-05 |
Lipocine, Inc. |
Pharmaceutical compositions with synchronized solubilizer release
|
|
US7507823B2
(en)
|
2004-05-06 |
2009-03-24 |
Bristol-Myers Squibb Company |
Process of making aripiprazole particles
|
|
US20080152714A1
(en)
*
|
2005-04-08 |
2008-06-26 |
Yi Gao |
Pharmaceutical Formulations
|
|
JP2007308480A
(ja)
*
|
2006-04-20 |
2007-11-29 |
Shin Etsu Chem Co Ltd |
腸溶性固体分散体を含んでなる固形製剤
|
|
US20070275052A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Glenmark Pharmaceuticals Limited |
Pharmaceutical compositions containing sterol inhibitors
|
|
CA2656277A1
(en)
*
|
2006-06-26 |
2008-01-03 |
Mutual Pharmaceutical Company, Inc. |
Active agent formulations, methods of making, and methods of use
|
|
US8946200B2
(en)
*
|
2006-11-02 |
2015-02-03 |
Southwest Research Institute |
Pharmaceutically active nanosuspensions
|
|
ZA200905094B
(en)
*
|
2006-12-22 |
2010-09-29 |
Yuhan Corp |
Revaprazan-containing solid dispersion and process for the preparation thereof
|
|
US20100151035A1
(en)
*
|
2007-03-13 |
2010-06-17 |
Sandoz Ag |
Pharmaceutical compositions of poorly soluble drugs
|
|
US8404850B2
(en)
*
|
2008-03-13 |
2013-03-26 |
Southwest Research Institute |
Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
|
|
US8861813B2
(en)
*
|
2008-03-13 |
2014-10-14 |
Mallinckrodt Llc |
Multi-function, foot-activated controller for imaging system
|
|
EP2278957A2
(en)
*
|
2008-04-15 |
2011-02-02 |
Schering Corporation |
Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
|
|
CN104983701A
(zh)
*
|
2008-04-15 |
2015-10-21 |
默沙东公司 |
优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物
|
|
US8722706B2
(en)
*
|
2008-08-15 |
2014-05-13 |
Southwest Research Institute |
Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
|
|
US8309134B2
(en)
*
|
2008-10-03 |
2012-11-13 |
Southwest Research Institute |
Modified calcium phosphate nanoparticle formation
|
|
US20100159010A1
(en)
*
|
2008-12-24 |
2010-06-24 |
Mutual Pharmaceutical Company, Inc. |
Active Agent Formulations, Methods of Making, and Methods of Use
|
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
|
JO3002B1
(ar)
|
2009-08-28 |
2016-09-05 |
Irm Llc |
مركبات و تركيبات كمثبطات كيناز بروتين
|
|
US9028873B2
(en)
*
|
2010-02-08 |
2015-05-12 |
Southwest Research Institute |
Nanoparticles for drug delivery to the central nervous system
|
|
US9358241B2
(en)
|
2010-11-30 |
2016-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
|
US9034858B2
(en)
|
2010-11-30 |
2015-05-19 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
|
DK2782557T3
(en)
*
|
2011-11-23 |
2018-12-10 |
Array Biopharma Inc |
PHARMACEUTICAL FORMULATIONS
|
|
US9650851B2
(en)
|
2012-06-18 |
2017-05-16 |
Schlumberger Technology Corporation |
Autonomous untethered well object
|
|
KR20210043721A
(ko)
*
|
2012-06-21 |
2021-04-21 |
메인 파마 인터내셔널 프로프라이어터리 리미티드 |
이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법
|
|
US9192609B2
(en)
|
2013-04-17 |
2015-11-24 |
Hedgepath Pharmaceuticals, Inc. |
Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
|
|
EP2837391B1
(en)
|
2013-08-12 |
2017-05-10 |
Shin-Etsu Chemical Co., Ltd. |
Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
|
|
CN104644557B
(zh)
*
|
2013-11-22 |
2017-10-31 |
上海宣泰医药科技有限公司 |
卟啉铁固体分散体及其制备方法
|
|
US9498485B2
(en)
|
2014-08-28 |
2016-11-22 |
Lipocine Inc. |
Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
|
|
US20170246187A1
(en)
|
2014-08-28 |
2017-08-31 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
|
CA2987867C
(en)
|
2015-06-09 |
2023-06-27 |
Capsugel Belgium Nv |
Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
|
|
US20160361322A1
(en)
|
2015-06-15 |
2016-12-15 |
Lipocine Inc. |
Composition and method for oral delivery of androgen prodrugs
|
|
US11559530B2
(en)
|
2016-11-28 |
2023-01-24 |
Lipocine Inc. |
Oral testosterone undecanoate therapy
|
|
EP3570839B1
(en)
*
|
2017-01-20 |
2020-12-02 |
Constellation Pharmaceuticals, Inc. |
Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
|
|
EP3669191A4
(en)
|
2017-08-20 |
2021-04-14 |
University of Connecticut |
NITROGEN-TYPE COMPOUND ANALOGUES AND THEIR METHODS OF USE
|
|
EP3824296A4
(en)
|
2018-07-20 |
2022-04-27 |
Lipocine Inc. |
LIVER DISEASE
|
|
WO2020159562A1
(en)
|
2019-01-29 |
2020-08-06 |
Slayback Pharma Llc |
Pharmaceutical compositions of posaconazole
|
|
US11318107B2
(en)
|
2019-02-22 |
2022-05-03 |
Avior, Inc. |
Pharmaceutical active-containing film delivery device for oral transmucosal administration
|
|
WO2021030174A1
(en)
|
2019-08-09 |
2021-02-18 |
University Of Connecticut |
Truncated itraconazole analogues and methods of use thereof
|
|
US20220401425A1
(en)
*
|
2019-08-28 |
2022-12-22 |
Shenzhen Chipscreen Biosciences Co., Ltd. |
Chidamide pharmaceutical composition, preparation method therefor and application thereof
|
|
CN115768779A
(zh)
|
2020-05-07 |
2023-03-07 |
上海偕怡医药科技有限公司 |
伊曲康唑前药及其用途
|